| |
| Issue |
Title |
| |
| Vol 13, No 2 (2023) |
Which patients with myocardial infarction can be prescribed only P2Y12 inhibitor and stop using aspirin? |
Abstract
PDF (Rus)
|
|
A. L. Komarov |
| |
| Vol 13, No 2 (2023) |
Sensitivity to clopidogrel and outcomes of long-term dual antiplatelet therapy in patients with multifocal atherosclerosis |
Abstract
PDF (Rus)
|
|
M. B. Khakimova, A. L. Komarov, A. B. Dobrovolsky, E. V. Titaeva, V. V. Kadochnikova, D. D. Abramov, E. P. Panchenko |
| |
| Vol 13, No 2 (2023) |
Treatment of pulmonary embolism in "fragile" patients |
Abstract
PDF (Rus)
|
|
V. I. Golovina, V. A. Panfilov, I. A. Zolotukhin |
| |
| Vol 13, No 1 (2023) |
The role of acetylsalicylic acid in the treatment of diseases caused by atherosclerosis |
Abstract
PDF (Rus)
|
|
I. S. Yavelov |
| |
| Vol 13, No 1 (2023) |
The efficacy and safety of apixaban: what has changed in 12 years of its use in real clinical practice? |
Abstract
PDF (Rus)
|
|
E. Р. Panchenko |
| |
| Vol 12, No 2 (2022) |
Acetylsalicylic acid in the primary prevention of vascular complications in patients without clinically apparent atherosclerosis: how to balance risk and benefit? |
Abstract
PDF (Rus)
|
|
A. L. Komarov |
| |
| Vol 12, No 2 (2022) |
Safety of discontinuation of anticoagulants after venous thromboembolism: whether D-dimer level should be taken into account? |
Abstract
PDF (Rus)
|
|
I. S. Yavelov |
| |
| Vol 12, No 2 (2022) |
Is there still room for warfarin after the appearance of direct oral anticoagulants? |
Abstract
PDF (Rus)
|
|
E. P. Panchenko |
| |
| Vol 12, No 1 (2022) |
Current approaches to the selection of acetylsalicylic acid dosage forms in cardiology |
Abstract
PDF (Rus)
|
|
S. R. Gilyarevskiy, M. V. Golshmid, N. G. Bendeliani, I. M. Kuzmina |
| |
| Vol 12, No 1 (2022) |
Modern possibilities and prospects in evaluating the anticoagulant effect of direct oral anticoagulants |
Abstract
PDF (Rus)
|
|
A. I. Mironova, E. S. Kropacheva, A. B. Dobrovolsky, E. V. Titaeva, E. P. Panchenko |
| |
| No 2 (2021) |
Sulodexide as pharmacotherapy for protection of endothelium and suppression of thrombosis in COVID-19 |
Abstract
PDF (Rus)
|
|
A. M. Melkumyants, L. I. Buryachkovskaya, N. V. Lomakin, O. A. Antonova, V. V. Ermiskin, Y. V. Dotsenko |
| |
| No 2 (2021) |
Persistent risk of vascular complications and efficacy of prolonged dual antiplatelet therapy after myocardial infarction |
Abstract
PDF (Rus)
|
|
I. S. Yavelo |
| |
| No 2 (2021) |
Long-term outcomes of coronary artery bypass graft surgery in patients with widespread atherosclerotic lesions of the coronary and peripheral vascular basins (based on the REGATA long-term antithrombotic therapy registry) |
Abstract
PDF (Rus)
|
|
E. N. Krivosheeva, A. L. Komarov, D. M. Galyautdinov, E. E. Vlasova, R. S. Akchurin, E. P. Panchenko |
| |
| No 2 (2021) |
Characteristics of patients with active cancer and venous thromboembolic complications receiving a chemotherapy treatment cycle (according to the ‘real-life’ clinical practice of Publicly Funded Health Facility: Moscow City Oncology Hospital No. 62 of Moscow Healthcare Department) |
Abstract
PDF (Rus)
|
|
J. A. Fedotkina, O. O. Frolkova, D. Y. Kanner, A. A. Kalygin, E. P. Panchenko |
| |
| No 1 (2021) |
Anticoagulants and antiaggregants in the COVID-19 era |
Abstract
PDF (Rus)
|
|
A. D. Erlikh |
| |
| No 1 (2021) |
Rivaroxaban in patients with atrial fibrillation: from research to real practice (based on REGistry of Long-term AnTithrombotic TherApy-2 (REGATA)) |
Abstract
PDF (Rus)
|
|
E. S. Kropacheva, E. N. Krivosheeva, E. P. Panchenko |
| |
| No 1 (2021) |
Modern concepts of the place of acetylsalicylic acid in the treatment of patients with various manifestations of atherothrombosis |
Abstract
PDF (Rus)
|
|
E. P. Panchenko |
| |
| No 1 (2021) |
The risk of bleeding minimization with direct oral anticoagulants |
Abstract
PDF (Rus)
|
|
Т. N. Novikova |
| |
| No 2 (2020) |
Regarding the choice of Р2У12 platelet receptor blocker in the early invasive approach to acute coronary syndrome treatment in patients without indications for long-term anticoagulant use |
Abstract
PDF (Rus)
|
|
I. S. Yavelov |
| |
| No 2 (2020) |
Antithrombotic therapy for chronic ischemic heart disease: how to balance risk and benefit in different categories of patients? |
Abstract
PDF (Rus)
|
|
N. B. Perepech |
| |
| No 2 (2020) |
Antithrombotic therapy in patients with atrial fibrillation and percutaneous coronary intervention: what has changed in the guidelines in 2020? |
Abstract
PDF (Rus)
|
|
E. P. Panchenko |
| |
| No 1 (2020) |
Thrombus of left atrium and/or its appendage in nonvalvular atrial fibrillation: echocardiographic and laboratory risk factors, capabilities for prediction and correction |
Abstract
PDF (Rus)
|
|
I. A. Zaigraev, I. S. Yavelov |
| |
| No 1 (2020) |
The role of clopidogrel in the current treatment of acute coronary syndrome |
Abstract
PDF (Rus)
|
|
I. S. Yavelov |
| |
| No 1 (2020) |
Topical issues of dabigatran use in combination antithrombotic therapy in patients with acute coronary syndrome and nonvalvular atrial fibrillation |
Abstract
PDF (Rus)
|
|
N. A. Novikova, A. S. Shilova |
| |
| No 1 (2020) |
Apixaban role in the treatment of venous thromboembolic complications in patients with active cancer |
Abstract
PDF (Rus)
|
|
E. P. Panchenko |
| |
| No 2 (2019) |
THROMBUS OF LEFT ATRIUM AND/OR ITS APPENDAGE IN CASE OF NONVALVULAR ATRIAL FIBRILLATION: FREQUENCY OF DETECTION AND CLINICAL RISK FACTORS |
Abstract
PDF (Rus)
|
|
I. A. Zaigrayev, I. S. Yavelov |
| |
| No 2 (2019) |
CASE OF LEFT ATRIUM INTRAMURAL HEMATOMA AFTER PERCUTANEOUS CORONARY INTERVENTION |
Abstract
PDF (Rus)
|
|
T. S. Sukhinina, R. M. Shakhnovich, D. V. Pevzner, T. N. Veselova, N. S. Zhukova, I. N. Merkulova, V. N. Shitov, O. V. Stukalova, V. M. Mironov, S. K. Ternovoy, I. I. Staroverov |
| |
| No 2 (2019) |
EVALUATION OF EFFICACY AND SAFETY OF ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION IN PROSPECTIVE FOLLOW-UP |
Abstract
PDF (Rus)
|
|
M. V. Khruslov, M. A. Karpenko, T. V. Vavilova, T. A. Barbashina, A. S. Sorokina, E. V. Kovaleva, D. V. Eliseeva, N. V. Vasilievа, L. V. Safronova, I. V. Ponomareva, V. S. Kucherenko |
| |
| No 2 (2019) |
COMPARATIVE CHARACTERISTICS OF MULTIMORBIDITY, DRUG TREATMENT AND OUTCOMES IN POSTSTROKE PATIENTS WITH ATRIAL FIBRILLATION AND WITH OR WITHOUT HISTORY OF MYOCARDIAL INFARCTION (REGISTRY REGION DATA) |
Abstract
PDF (Rus)
|
|
E. Yu. Okshina, M. M. Loukianov, S. Yu. Martsevich, S. S. Yakushin, N. P. Kutishenko, I. S. Yavelov, A. N. Vorobyev, K. G. Pereverzeva, A. V. Zagrebelnyy, N. A. Dmitrieva, E. V. Kudryashov, S. A. Boytsov, O. M. Drapkina, K. A. Moseichuk |
| |
| No 1 (2019) |
ASPECTS OF MULTICOMPONENT THERAPY AND PERIOPERATIVE TACTICS IN A PATIENT WITH ATRIAL FIBRILLATION RECEIVING RIVAROXABAN THERAPY. CLINICAL OBSERVATION |
Abstract
PDF (Rus)
|
|
O. A. Zemlyanskaya, E. S. Kropacheva |
| |
| No 1 (2019) |
POSSIBILITIES OF INHIBITING ANTICOAGULANT ACTIVITIES THAT INHIBIT XA-FACTOR |
Abstract
PDF (Rus)
|
|
A. D. Erlich |
| |
| No 1 (2019) |
CLINICAL CASE OF RESUMPTION OF ANTICOAGULANT THERAPY AFTER IMPLANTATION OF THE AMPLATZER CARDIAC PLUG LEFT ATRIAL APPENDAGE OCCLUDER |
Abstract
PDF (Rus)
|
|
R. V. Guchaev, D. V. Pevzner, E. V. Merkulov, M. I. Makeev, N. S. Zhukova, R. M. Shakhnovich, T. Yu. Vedenikin, N. V. Shestakova |
| |
| No 2 (2018) |
CLINICAL IMPRESSION: PLANNED PERCUTANEOUS CORONARY INTERVENTION IN A PATIENT WITH ATRIAL FIBRILLATION |
Abstract
PDF (Rus)
|
|
Andrei I. Komarov |
| |
| No 1 (2018) |
RANDOMIZED CLINICAL TRIALS AND REVIEW OF EVERYDAY CLINICAL PRACTICE: WHAT IT MEANS FOR THE CLINICIAN. LECTURE |
Abstract
PDF (Rus)
|
|
I. S. Yavelov |
| |
| No 1 (2018) |
PRASUGREL FOR THE TREATMENT OF ACUTE CORONARY SYNDROMES AND PERCUTANEOUS CORONARY INTERVENTION: STATUS UPDATE ON THE PROBLEM |
Abstract
PDF (Rus)
|
|
O. O. Shakhmatova, A. L. Komarov |
| |
| No 1 (2018) |
ON THE POSSIBILITIES OF ATTENUATION OF ANTIPLATELET THERAPY INTENSITY IN PATIENTS AFTER ACUTE CORONARY SYNDROME. RESOLUTION OF THE PANEL OF EXPERTS OF THE EMERGENCY CARDIOLOGY SOCIETY |
Abstract
PDF (Rus)
|
|
Article Editorial |
| |
| No 1 (2018) |
STRATEGY TO MINIMIZE THE BLEEDING RISKS IN PATIENTS WITH ATRIAL FIBRILLATION WHO RECEIVE COMBINED ANTITHROMBOTIC THERAPY AFTER PERCUTANEOUS CORONARY INTERVENTION |
Abstract
PDF (Rus)
|
|
D. A. Zateishchikov |
| |
| No 2 (2017) |
ROLE OF ANTITHROMBIN IN DIAGNOSTICS AND INTENSIVE THERAPY OF ACUTE DIC-SYNDROME (review of literature and evidence of actual clinical practice) |
Abstract
PDF (Rus)
|
|
N. A. VOROBIEVA |
| |
| No 2 (2017) |
INDIVIDUAL APPROACH TO PATIENTS WITH INDICATION FOR ANTIPLATELET THERAPY. WHAT TO RELY ON IN CHOOSING THE THERAPY? |
Abstract
PDF (Rus)
|
|
N. V. LOMAKIN, A. B. SUMAROKOV, Yu. V. DOTSENKO, I. A. UCHITEL, L. I. BURYACHKOVSKAYA |
| |
| No 2 (2017) |
CLINICAL DISCUSSION OF A PATIENT WITH RECURRENT VENOUS THROMBOEMBOLIC COMPLICATIONS |
Abstract
PDF (Rus)
|
|
A. L. KOMAROV |
| |
| No 1 (2017) |
SELECTING AN OPTIMAL LONG-TERM ANTICOAGULANT THERAPY FOR A PATIENT WITH ATRIAL FIBRILLATION AND RECURRENT MINOR HEMORRHAGE. CLINICAL FOLLOW-UP |
Abstract
PDF (Rus)
|
|
E. S. Kropacheva, E. P. Panchenko |
| |
| No 1 (2017) |
THE SPECIFICS OF PRESCRIBING TRIPLE ANTITROMBOTIC THERAPY WITH RIVAROXABAN IN PATIENTS WITH ATRIAL FIBRILLATION AFTER CORONARY ARTERY STENTING |
Abstract
PDF (Rus)
|
|
N. A. Novikova, A. S. Shilova |
| |
| No 1 (2017) |
CURRENT VIEWS ON ANTITHROMBOTIC THERAPY IN NON-CARDIOEMBOLIC STROKE |
Abstract
PDF (Rus)
|
|
A. V. Fonyakin, L. A. Geraskina |
| |
| No 1 (2016) |
WARFARIN: PLACE IN THE ANTICOAGULANT THERAPY TODAY |
Abstract
PDF (Rus)
|
|
N. A. Novikova, A. N. Volovchenko |
| |
| No 1 (2016) |
DURATION OF DUAL ANTIPLATELET THERAPY |
Abstract
PDF (Rus)
|
|
O. L. Barbarash |
| |
| No 1 (2016) |
EFFICACY AND SAFETY OF DIRECT ORAL ANTICOAGULANTS IN THE PREVENTION OF STROKE IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION IN EVERYDAY CLINICAL PRACTICE: FACTS ABOUT RIVAROXABAN |
Abstract
PDF (Rus)
|
|
I. S. Yavelov |
| |
| No 1 (2016) |
SPECIFIC ANTIDOTES TO NEW ORAL ANTICOAGULANTS |
Abstract
PDF (Rus)
|
|
O. O. Shakhmatova |
| |
| 1 - 47 of 47 Items |
|
